{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"condition":["Colorectal Neoplasms","Unresectable or Metastatic Colorectal Cancer"],"disease":["Colorectal Neoplasms","Unresectable Or Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/13708"],"location":["China"],"study_start_month":["8"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ) in the Treatment of Unresectable or Metastatic Colorectal Cancer","description":"To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ) in first-line treatment of unresectable or metastatic colorectal cancer","dates":{"creation":"2022-08-15"},"accession":"13708","cross_references":{"ClinicalTrials___gov":["NCT05797883"]}}